Suppr
超能文献

多西他赛联合顺铂加氟尿嘧啶与卡铂加氟尿嘧啶-西妥昔单抗用于既往未接受新辅助或辅助化疗的复发或转移性头颈部鳞状细胞癌患者一线治疗，哪种方案为标准方案？

Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?

作者信息

Mutlu Hasan, Salim Derya Kıvrak, Gündüz Şeyda, Eryılmaz Melek Karakurt, Musri Fatma Yalçın, Coşkun Hasan Şenol

机构信息

Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.

Department of Antalya Research and Training Hospital, Antalya, Turkey.

出版信息

J Cancer Res Ther. 2017 Jul-Sep;13(3):510-513. doi: 10.4103/0973-1482.161933.

DOI:10.4103/0973-1482.161933

PMID:28862218

Abstract

BACKGROUND

The prognosis of recurrent or metastatic head and neck squamous cell cancer (HNSCC) is very poor. In the present retrospective study, we compared the impact of docetaxel plus cisplatin plus fluorouracil (TCF), and cisplatin plus fluorouracil plus cetuximab (CF-Ctx) regimens on the prognosis of patients with recurrent or metastatic HNSCC in first-line.

MATERIALS AND METHODS

A total of 70 patients were evaluated as two groups, according to treatment protocol: TCF (n: 47) and CF-Ctx (n: 23). The groups were compared regarding survival.

RESULTS

The median progression-free survival was 7.3 and 8.3 months, TCF and CF-Ctx groups, respectively, (P = 0.280). The median overall survival (OS) was 15.6 and 9.3 months for TCF and CF-Ctx groups, respectively, (P = 0.029). The dose reduction and using of granulocyte colony stimulating factor were significantly higher in TCF group (P = 0.048 and P = 0.018, respectively).

CONCLUSION

In first-line setting, TCF regimen is superior to CF-Ctx regimen in terms of OS in patients with recurrent or metastatic HNSCC, who did not previously receive neoadjuvant or adjuvant chemotherapy.

摘要

背景

复发或转移性头颈部鳞状细胞癌（HNSCC）的预后非常差。在本回顾性研究中，我们比较了多西他赛联合顺铂加氟尿嘧啶（TCF）方案与顺铂加氟尿嘧啶加西妥昔单抗（CF-Ctx）方案对一线复发或转移性HNSCC患者预后的影响。

材料与方法

根据治疗方案将70例患者分为两组：TCF组（n = 47）和CF-Ctx组（n = 23）。比较两组的生存率。

结果

TCF组和CF-Ctx组的无进展生存期（PFS）中位数分别为7.3个月和8.3个月（P = 0.280）。TCF组和CF-Ctx组的总生存期（OS）中位数分别为15.6个月和9.3个月（P = 0.029）。TCF组的剂量减少和粒细胞集落刺激因子的使用显著更高（分别为P = 0.048和P = 0.018）。